Reported Earlier, Humacyte Prices $40.2M Public Offering Of 13.4M Common Stock At $3/Share

Author: Benzinga Newsdesk | March 01, 2024 04:08am

Humacyte intends to use the net proceeds that it will receive from the offering to continue the advancement of its pipeline in regenerative medicine, to support U.S. Food and Drug Administration's ("FDA") review of its Biologics License Application ("BLA") seeking approval of Humacyte's bioengineered human acellular vessels ("HAVs") in urgent arterial repair following extremity vascular trauma when synthetic graft is not indicated and when autologous vein use is not feasible, to establish its initial commercial infrastructure in anticipation of future potential commercial launches and for general corporate purposes.

Posted In: HUMA